Online inquiry

IVTScrip™ pT7-VEE-mRNA-β gal Vector   (CAT#: GTVCR-WQ005MR)

The vector is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies, protein expression, and biological imaging. The system was driven by the T7 promoter to efficiently generate β-gal mRNA through T7 RNA polymerase and nucleotides under appropriate reaction conditions. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
5' UTR Kozak seq
Resistance Ampicillin
Species E coli
RefSeq NP_414878.1
Applications Reporter gene; IVT; Self-amplifying mRNA (SAM) research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-β gal Vector (GTVCR-WQ005MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2097MR IVTScrip™ pSP6-VEE-mRNA-Anti-PDCD1, NPVPDR001 Vector Vector NPVPDR001
GTVCR-WQ784MR IVTScrip™ pT7-VEE-mRNA-Anti-FGFR1, BMS-986036 Vector Vector BMS-986036
GTVCR-WQ1759MR IVTScrip™ pT7-VEE-mRNA-Anti-APP, LY3002813 Vector Vector LY3002813
GTVCR-WQ1710MR IVTScrip™ pSP6-VEE-mRNA-Anti-ITGA4&ITGB7, LDP-02 Vector Vector LDP-02
GTVCR-WQ1905MR IVTScrip™ pSP6-VEE-mRNA-Anti-IGF, MEDI-573 Vector Vector MEDI-573
GTVCR-WQ1998MR IVTScrip™ pSP6-VEE-mRNA-Anti-GUCY2C, MLN2045 Vector Vector MLN2045
GTVCR-WQ517MR IVTScrip™ pSP6-VEE-mRNA-Anti-PTK7, Anti-PTK7 ADC Vector Vector Anti-PTK7 ADC
GTVCR-WQ1084MR IVTScrip™ pT7-VEE-mRNA-Anti-HA, CT-P23 Vector Vector CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW